Business
Positive Final Results Returned from Phase 2 Clinical Trials using Satipharm Capsules
Positive Final Results Returned from Phase 2 Clinical Trials using Satipharm Capsules ...
About this update from Delivra Health Brands Inc
[{"type":"text","content":"\n\n\n\nPositive Final Results Returned from Phase 2 Clinical Trials using Satipharm Capsules\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, July 24, 2018\n\n\n\nTSXV – HVT\n\n\n\nVANCOUVER, July 24, 2018 /CNW/ - Harvest One Cannabis Inc. (TSXV: HVT) (\"Harvest One\" or the \"Company\"), through its wholly-owned subsidiary Satipharm AG (\"Satipharm\"), is pleased to advise that positive results have been returned from the completed Phase 2 clinical trials undertaken by Israeli-based PhytoTech Therapeutics (\"PTL\") that used Satipharm's proprietary CBD capsules. The completed Phase 2 trial is an open-label, single-centre clinical study to evaluate the safety, tolerability and efficacy of oral administration of Satipharm CBD capsules as an adjunctive treatment. As previously announced, Harvest One is to acquire PTL from MMJ PhytoTech Limited (\"MMJ\"), pending MMJ shareholder and TSXV approval. \n\n\n \n \n\n \n\"This is a step forward for Harvest One's pharma and nutraceutical strategy,\" said Grant Froese, CEO of Harvest One. \"Continuing to develop products that will aid individuals and enrich their lives will continue to be a core component of our medical strategy moving forward. These results show that Harvest One is on track to be a leading provider of innovative medical cannabis products in the years to come.\" \n\nKey findings of the trial\n\n\nSatipharm's CBD capsules significantly reduced monthly seizures in treatment resistant children when added to current medications. The median reduction was -82% in the 12-week treatment period.\n9/16 patients (56%) who started the treatment had a reduction of at least 50% in total number of seizures during the entire treatment period, compared to observation\nFollowing 12 weeks of treatment, 8/11 patients (73%) were rated as \"very much improved/improved\" in overall condition on the Caregiver Global Impression of Improvement scale and 9/11 patients (82%) were rated as \"very much reduced/reduced\" on that scale\n\nProf. Uri Kramer, Director of Pediatric Epilepsy Service, Tel Aviv Soura...